Unicycive Therapeutics, Inc. (Nasdaq: UNCY) announced on November 16, 2026, that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC). The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.
The resubmission was necessitated by a Complete Response Letter (CRL) received in June 2026, which cited deficiencies related to the original Drug Product (DP) vendor. The company stated that the June 2026 CRL did not raise concerns regarding clinical efficacy or safety data. The resubmitted NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new DP manufacturing vendor. This new vendor's facility was last inspected by the FDA in March 2024 and received a "No Action Indicated" status. The company noted that it does not know if the FDA will conduct a pre-approval inspection of this vendor. Additionally, the original DP vendor was recently inspected; if the FDA determines it complies with current Good Manufacturing Practice (cGMP), the company plans to discuss whether this could shorten the review timeline.
In preparation for a potential launch, Unicycive is advancing commercial readiness initiatives. The company is in active discussions with key commercial leaders to bring them on board in the first quarter of 2027 and plans to hire an optimized sales force targeting physician prescribers upon approval. Discussions are also ongoing with dialysis organizations. Regarding reimbursement, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule on October 28, 2026. This rule establishes permanent phosphate binder funding through a $12.85 per-treatment addition to the base rate effective January 1, 2027. Unicycive believes OLC meets the criteria for the Transitional Drug Add-on Payment Adjustment (TDAPA) upon FDA approval, which could allow for two years of separate reimbursement at 100% of average sales price.
For the third quarter ended September 30, 2026, Unicycive reported Research and Development (R&D) expenses of $2.2 million and General and Administrative (G&A) expenses of $6.6 million. The company reported a net loss attributable to common stockholders of $7.0 million, or $0.25 per share. As of September 30, 2026, the company held approximately $59 million in cash, cash equivalents, and marketable securities, with expected runway beyond 2027, including anticipated launch expenses.